Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
retinoic acid/vracanie
Odkaz sa uloží do schránky
Strana 1 od 26 výsledky
Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
Prompted by recent demonstrations that all-trans-retinoic acid (all-trans-RA) had efficacy in acute promyelocytic leukemia, a phase I trial of all-trans-RA was conducted to establish the maximum-tolerated dose (MTD) before phase II testing.
METHODS
Forty patients with a histologic or
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
All trans retinoic acid has shown a remarkable effectiveness in acute promyelocytic leukemia. These results have encouraged studies of treatment with ATRA in other acute myeloid leukemia subtypes.
METHODS
In order to evaluate toxicity and antileukemic efficacy of all ATRA in patients with
Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
Thirteen-cis retinoic acid (RA) has been shown to have growth-inhibitory and differentiative activity on non-small cell lung cancer (NSCLC) cells in vitro. This promoted the rationale for combining RA with three active drugs, cisplatin (CDDP) vindesine (VDS) and mitomycin-c (MMC) in the
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
We conducted a study to evaluate the tolerance to and biologic effects of all-trans retinoic acid in patients with myelodysplastic syndrome.
METHODS
Thirty-nine patients with myelodysplastic syndrome were treated with oral all-trans retinoic acid for 6 weeks. Dose levels were 10, 25, 50,
Phase II trial of 13-cis-retinoic acid in metastatic breast cancer.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Studies have suggested that both natural and synthetic retinoids have extensive chemopreventive activity against a variety of carcinogens in vivo and in vitro. We have previously shown that growth of human breast cancer cells can be inhibited by retinoids, and retinoic acid-binding proteins have
[Hypercalcemia associated with all-trans retinoic acid therapy for microgranular type acute promyelocytic leukemia].
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
A 24-year-old man was admitted to the hospital for pancytopenia. Peripheral blood test and bone marrow aspiration demonstrated an increase in hypogranular promyelocytes. Karyotype analysis and RT-PCR showed 47, XY, t(15;17)(q22;q12), +12, and PML-RARA, respectively. The patient was diagnosed as
Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha 2a has been reported to be highly active in previously untreated squamous carcinoma of the cervix. In this phase II study, 13-cRA was given at a dose of 1 mg/kg/day and IFN-alpha 2a was given subcutaneously at a dose of 3
Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
To determine the response rate and toxicity of oral 13-cis-retinoic acid (CRA) added to an outpatient regimen of subcutaneous interleukin-2 (IL2) and interferon-alpha (IFNA) in previously untreated patients with metastatic renal-cell carcinoma (RCC).
METHODS
Eligibility included a
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
The treatment of metastatic renal cell cancer remains unsatisfactory despite encouraging results with biotherapy. Pilot studies from other investigators have suggested that combining cis-retinoic acid and 5-fluorouracil (5FU) with interleukin-2 (IL-2) and interferon-alpha (IFN) may
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
A 55-year-old woman developed acute promyelocytic leukaemia during treatment with all-trans-retinoic acid and arsenic trioxide. Initially, she presented with symptoms of epigastric pain, vomiting, and nausea, and she developed acute pancreatitis. She was treated with parenteral nutritional
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
To determine the maximum-tolerated dose (MTD) of all-trans-retinoic acid (ATRA) administered on an intermittent oral schedule with interferon-alpha2a (IFN-alpha2a) in children with refractory cancer, and whether the marked reduction in plasma ATRA concentrations observed with chronic daily
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
PURPOSE
The reported maximum tolerated dose (MTD) of single-agent belinostat is 1000 mg/m2 given days 1-5, every 21 days. Pre-clinical evidence suggests histone deacetylase inhibitors enhance retinoic acid signaling in a variety of solid tumors. We conducted a phase IAll-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Retinoids have anti-tumor activity in several malignant and premalignant conditions. Since Kaposi's sarcoma is regulated by steroid hormones both in vivo and in vitro, we hypothesized that retinoids may have anti-tumor effects in AIDS-related Kaposi's sarcoma. Thus, 27 patients with mucocutaneous,
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults. Most patients diagnosed with AML are at advanced age and present with co-morbidities, so that intensive therapy such as stem cell transplantation (SCT) is impossible to provide or is accompanied by high risks for
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation. Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy. This phase I trial was
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
